Insider trade

CEO exercised or converted 20K GILD derivative securities

Traded Mar 10, 2026 · Filed Mar 12, 2026

Gilead SciencesGILD

20K
Shares

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 10, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 12, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001638643-26-000014

Filed / recorded

Mar 12, 2026, 8:24 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Ticker

GILD

Reporting person

Daniel Patrick O'day

Relationship

Director, Officer

Officer title

Chairman & CEO

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Mar 10, 2026

Transaction code

M

Shares / units

20,026

Acquired / disposed

Acquired (A)

Shares owned after

662,334

Ownership form

Direct

Amendment

No

Footnotes from the filing

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Around the same time

CEO sold ~$1.37M of Gilead Sciences

Scheduled in advance6mo ago

Officer sold ~$433K of Gilead Sciences

Scheduled in advance7mo ago

CFO sold ~$433K of Gilead Sciences

Scheduled in advance7mo ago